Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone (vol 11, pg E1743, 2023)

被引：0
|
作者：
不详
机构：
来源：
LANCET GLOBAL HEALTH | 2024年 / 12卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：E32 / E32
页数：1
相关论文
共 22 条
  • [1] Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active- controlled trial in Guinea and Sierra Leone
    Choi, Edward Man-Lik
    Lacarra, Boris
    Afolabi, Muhammed
    Ale, Boni Maxime
    Baiden, Frank
    Betard, Christine
    Foster, Julie
    Hamze, Benjamin
    Schwimmer, Christine
    Manno, Daniela
    D'Ortenzio, Eric
    Ishola, David
    Keita, Cheick Mohamed
    Keshinro, Babajide
    Njie, Yusupha
    van Dijck, Wim
    Gaddah, Auguste
    Anumendem, Dickson
    Lowe, Brett
    Vatrinet, Renaud
    Lawal, Bolarinde Joseph
    Otieno, Godfrey
    Samai, Mohamed
    Deen, Gibrilla Fadlu
    Swaray, Ibrahim Bob
    Kamara, Abu Bakarr
    Kamara, Michael Morlai
    Diagne, Mame Aminata
    Kowuor, Dickens
    McLean, Chelsea
    Leigh, Bailah
    Beavogui, Abdoul Habib
    Leyssen, Maarten
    Luhn, Kerstin
    Robinson, Cynthia
    Douoguih, Macaya
    Greenwood, Brian
    Thiebaut, Rodolphe
    Watson-Jones, Deborah
    LANCET GLOBAL HEALTH, 2023, 11 (11): : E1743 - E1752
  • [2] Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
    Afolabi, Muhammed O.
    Ishola, David
    Manno, Daniela
    Keshinro, Babajide
    Bockstal, Viki
    Rogers, Baimba
    Owusu-Kyei, Kwabena
    Serry-Bangura, Alimamy
    Swaray, Ibrahim
    Lowe, Brett
    Kowuor, Dickens
    Baiden, Frank
    Mooney, Thomas
    Smout, Elizabeth
    Kohn, Brian
    Otieno, Godfrey T.
    Jusu, Morrison
    Foster, Julie
    Samai, Mohamed
    Deen, Gibrilla Fadlu
    Larson, Heidi
    Lees, Shelley
    Goldstein, Neil
    Gallagher, Katherine E.
    Gaddah, Auguste
    Heerwegh, Dirk
    Callendret, Benoit
    Luhn, Kerstin
    Robinson, Cynthia
    Greenwood, Brian
    Leyssen, Maarten
    Douoguih, Macaya
    Leigh, Bailah
    Watson-Jones, Deborah
    LANCET INFECTIOUS DISEASES, 2022, 22 (01): : 110 - 122
  • [3] Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
    Barry, Houreratou
    Lhomme, Edouard
    Surenaud, Mathieu
    Nouctara, Moumini
    Robinson, Cynthia
    Bockstal, Viki
    Valea, Innocent
    Somda, Serge
    Tinto, Halidou
    Meda, Nicolas
    Greenwood, Brian
    Thiebaut, Rodolphe
    Lacabaratz, Christine
    PLOS NEGLECTED TROPICAL DISEASES, 2024, 18 (04):
  • [4] Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial
    Manno, Daniela
    Bangura, Agnes
    Baiden, Frank
    Kamara, Abu Bakarr
    Ayieko, Philip
    Kallon, Joseph
    Foster, Julie
    Conteh, Musa
    Connor, Nicholas Edward
    Koroma, Bockarie
    Njie, Yusupha
    Borboh, Paul
    Keshinro, Babajide
    Lawal, Bolarinde Joseph
    Kroma, Mattu Tehtor
    Otieno, Godfrey Tuda
    Deen, Abdul Tejan
    Choi, Edward Man-Lik
    Balami, Ahmed Dahiru
    Gaddah, Auguste
    McLean, Chelsea
    Luhn, Kerstin
    Adetola, Hammed Hassan
    Deen, Gibrilla Fadlu
    Samai, Mohamed
    Lowe, Brett
    Robinson, Cynthia
    Leigh, Bailah
    Greenwood, Brian
    Watson-Jones, Deborah
    LANCET INFECTIOUS DISEASES, 2023, 23 (03): : 352 - 360
  • [5] Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
    Ishola, David
    Manno, Daniela
    Afolabi, Muhammed O.
    Keshinro, Babajide
    Bockstal, Viki
    Rogers, Baimba
    Owusu-Kyei, Kwabena
    Serry-Bangura, Alimamy
    Swaray, Ibrahim
    Lowe, Brett
    Kowuor, Dickens
    Baiden, Frank
    Mooney, Thomas
    Smout, Elizabeth
    Kohn, Brian
    Otieno, Godfrey T.
    Jusu, Morrison
    Foster, Julie
    Samai, Mohamed
    Deen, Gibrilla Fadlu
    Larson, Heidi
    Lees, Shelley
    Goldstein, Neil
    Gallagher, Katherine E.
    Gaddah, Auguste
    Heerwegh, Dirk
    Callendret, Benoit
    Luhn, Kerstin
    Robinson, Cynthia
    Leyssen, Maarten
    Greenwood, Brian
    Douoguih, Macaya
    Leigh, Bailah
    Watson-Jones, Deborah
    LANCET INFECTIOUS DISEASES, 2022, 22 (01): : 97 - 109
  • [6] Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial (vol 22, pg 97, 2022)
    Ishola, D.
    Manno, D.
    Afolabi, M. O.
    LANCET INFECTIOUS DISEASES, 2023, 23 (09): : E337 - E337
  • [7] Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
    Pollard, Andrew J.
    Launay, Odile
    Lelievre, Jean-Daniel
    Lacabaratz, Christine
    Grande, Sophie
    Goldstein, Neil
    Robinson, Cynthia
    Gaddah, Auguste
    Bockstal, Viki
    Wiedemann, Aurelie
    Leyssen, Maarten
    Luhn, Kerstin
    Richert, Laura
    Betard, Christine
    Gibani, Malick M.
    Clutterbuck, Elizabeth A.
    Snape, Matthew D.
    Levy, Yves
    Douoguih, Macaya
    Thiebaut, Rodolphe
    LANCET INFECTIOUS DISEASES, 2021, 21 (04): : 493 - 506
  • [8] Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial
    Goldstein, Neil
    Mclean, Chelsea
    Gaddah, Auguste
    Doua, Joachim
    Keshinro, Babajide
    Bus-Jacobs, Linda
    Hendriks, Jenny
    Luhn, Kerstin
    Robinson, Cynthia
    Douoguih, Macaya
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [9] Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
    Anywaine, Zacchaeus
    Barry, Houreratou
    Anzala, Omu
    Mutua, Gaudensia
    Sirima, Sodiomon B.
    Eholie, Serge
    Kibuuka, Hannah
    Betard, Christine
    Richert, Laura
    Lacabaratz, Christine
    McElrath, M. Juliana
    De Rosa, Stephen C.
    Cohen, Kristen W.
    Shukarev, Georgi
    Katwere, Michael
    Robinson, Cynthia
    Gaddah, Auguste
    Heerwegh, Dirk
    Bockstal, Viki
    Luhn, Kerstin
    Leyssen, Maarten
    Thiebaut, Rodolphe
    Douoguih, Macaya
    PLOS MEDICINE, 2022, 19 (01)
  • [10] Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo
    Lariviere, Ynke
    Garcia-Fogeda, Irene
    Zola Matuvanga, Tresor
    Isekah Osang'ir, Bernard
    Milolo, Solange
    Meta, Rachel
    Kimbulu, Primo
    Robinson, Cynthia
    Katwere, Michael
    Mclean, Chelsea
    Hens, Niel
    Matangila, Junior
    Maketa, Vivi
    Mitashi, Patrick
    Muhindo-Mavoko, Hypolite
    Van Geertruyden, Jean-Pierre
    Van Damme, Pierre
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (04): : 1068 - 1076
123